Caxton Associates LP Protagonist Therapeutics, Inc Transaction History

Caxton Associates LP

  • $2.91 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$21.79 - $32.15 $349,664 - $515,911
16,047 New
16,047 $464,000
Q4 2022

Feb 14, 2023
BUY
$7.36 - $11.17 $160,838 - $244,098
21,853 New
21,853 $238,000
Q2 2022

Aug 15, 2022
BUY
$7.06 - $25.52 $433,272 - $1.57 Million
61,370 New
61,370 $485,000

Others Institutions Holding PTGX

# of Institutions
212
Shares Held
59.1M
Call Options Held
19K
Put Options Held
107K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email